Dr. Daniela Verzella is a type-A fixed-term researcher at the department of Biotechnological and Applied Clinical Sciences at the University of L'Aquila, Italy. She received her Master’s Degree in Medical Biotechnology and PhD in Experimental Medicine and Endocrinology from the University of L’Aquila in 2008 and 2012, respectively. She worked as a postdoc at the University of L’Aquila, where she studies the role of GADD45B in mediating the NF-kB-dependent anti-inflammatory and immunosuppressive signaling in cancer, and as a research associate at Imperial College London where she studies the role of NF-kB/GADD45B axis in mediating malignant cell survival and the therapeutic efficacy of new inhibitors targeting NF-kB downstream effectors in hematological cancers. Her research focuses on the identification of NF-kB target genes to develop novel therapeutic cancer-selective strategies targeting the NF-κB downstream effectors in human cancers.